Erasca (ERAS) Stock Chart & Stock Price History → Things Are Not Normal in America – Here’s What to Do (From Stansberry Research) (Ad) Free ERAS Stock Alerts $1.96 -0.19 (-8.84%) (As of 04:00 PM ET) Add Compare Share Share ChartStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Erasca Stock Price Performance5 Day Performance-8.41%1 Month Performance-13.27%3 Month Performance+6.52%6 Month Performance-2.49%Year-To-Date Performance-7.98%1 Year Performance-35.53% Receive ERAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter Email Address Ad Huge AlertsThis 1 Biotech Stock has been shocking the marketsSave the Date: BioStem's 2024 Q1 Call Coming Up!Sign Up for the Live Broadcast here ERAS Stock Chart for Thursday, May, 9, 2024 ERAS Chart by TradingView Erasca Share Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization05/08/2024$2.18$2.15-1.38%$2.18$2.10412,094 shs$372.72 million05/07/2024$2.21$2.18-1.36%$2.28$2.17770,362 shs$377.93 million05/06/2024$2.14$2.21+3.27%$2.21$2.10450,103 shs$383.12 million05/03/2024$2.15$2.14-0.47%$2.23$2.11261,791 shs$370.99 million05/02/2024$2.09$2.15+2.87%$2.17$2.03594,687 shs$372.72 million05/01/2024$2.01$2.09+3.98%$2.15$1.99655,085 shs$348.45 million Get the Latest News and Ratings for ERAS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter. 04/30/2024$2.04$2.01-1.47%$2.06$1.95399,171 shs$304.50 million04/29/2024$1.89$2.04+7.94%$2.07$1.89600,831 shs$309.04 million04/26/2024$1.88$1.89+0.53%$1.91$1.85255,588 shs$286.32 million04/25/2024$1.88$1.88$1.89$1.81466,394 shs$284.80 million04/24/2024$1.93$1.88-2.59%$1.95$1.86533,372 shs$284.80 million04/23/2024$1.85$1.93+4.32%$1.97$1.85442,813 shs$292.38 million04/22/2024$1.79$1.85+3.35%$1.88$1.79326,311 shs$280.26 million04/19/2024$1.79$1.79$1.82$1.74570,186 shs$271.17 million04/18/2024$1.84$1.79-2.72%$1.87$1.76648,069 shs$271.17 million04/17/2024$1.93$1.84-4.66%$1.96$1.84578,591 shs$278.74 million04/16/2024$2.00$1.93-3.50%$2.09$1.91734,923 shs$292.38 million04/15/2024$2.11$2.00-5.21%$2.13$1.97736,940 shs$302.98 million04/12/2024$2.29$2.11-7.86%$2.28$2.08583,551 shs$319.64 million04/11/2024$2.22$2.29+3.15%$2.31$2.22620,796 shs$346.91 million04/10/2024$2.26$2.22-1.77%$2.36$2.19875,286 shs$336.31 million04/09/2024$2.24$2.26+0.89%$2.44$2.231.22 million shs$342.37 million04/08/2024$2.10$2.24+6.67%$2.25$2.081.11 million shs$339.35 million04/05/2024$2.09$2.10+0.48%$2.12$2.04869,750 shs$318.13 million04/04/2024$2.17$2.09-3.69%$2.24$2.08442,445 shs$316.61 million04/03/2024$2.15$2.17+0.93%$2.18$2.07494,846 shs$328.73 million04/02/2024$2.16$2.15-0.46%$2.25$2.051.07 million shs$325.70 million04/01/2024$2.06$2.16+4.85%$2.25$1.991.27 million shs$327.22 million03/29/2024$2.06$2.06$2.59$2.031.90 million shs$311.25 million03/28/2024$2.06$2.06$2.59$2.031.90 million shs$311.25 million03/27/2024$1.98$2.06+4.04%$2.08$1.96289,480 shs$311.25 million03/26/2024$2.07$1.98-4.35%$2.13$1.98325,028 shs$299.16 million03/25/2024$2.15$2.07-3.72%$2.22$2.06339,909 shs$312.76 million03/22/2024$2.15$2.15$2.18$2.13466,161 shs$324.84 million03/21/2024$2.10$2.15+2.38%$2.19$2.08455,295 shs$324.84 million03/20/2024$2.05$2.10+2.44%$2.11$1.99311,119 shs$317.29 million03/19/2024$2.05$2.05$2.11$2.03369,301 shs$309.73 million03/18/2024$2.14$2.05-4.21%$2.24$2.05459,331 shs$309.73 million03/15/2024$2.08$2.14+2.88%$2.20$2.06852,701 shs$323.33 million03/14/2024$2.22$2.08-6.31%$2.21$2.07568,240 shs$314.26 millionCharles Payne Demystifies Options (Ad)When it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free.03/13/2024$2.14$2.22+3.74%$2.27$2.13607,416 shs$335.42 million03/12/2024$2.24$2.14-4.46%$2.26$2.10359,341 shs$323.33 million03/11/2024$2.28$2.24-1.75%$2.43$2.21505,251 shs$338.44 million03/08/2024$2.15$2.28+6.05%$2.36$2.18873,171 shs$344.49 million03/07/2024$2.22$2.15-3.15%$2.26$2.15596,731 shs$324.84 million03/06/2024$2.27$2.22-2.20%$2.30$2.16638,191 shs$335.42 million03/05/2024$2.35$2.27-3.40%$2.37$2.24761,459 shs$342.97 million03/04/2024$2.55$2.35-7.84%$2.58$2.29973,710 shs$355.06 million03/01/2024$2.38$2.55+7.14%$2.63$2.341.47 million shs$385.28 million02/29/2024$2.35$2.38+1.28%$2.50$2.332.57 million shs$359.59 million02/28/2024$2.46$2.35-4.47%$2.66$2.251.60 million shs$355.06 million02/27/2024$2.40$2.46+2.50%$2.62$2.401.62 million shs$371.68 million02/26/2024$2.32$2.40+3.45%$2.58$2.313.06 million shs$362.62 million02/23/2024$1.98$2.32+17.17%$2.44$1.982.92 million shs$350.53 million02/22/2024$1.92$1.98+3.13%$2.02$1.88672,783 shs$299.16 million02/21/2024$1.97$1.92-2.54%$2.02$1.89738,104 shs$290.09 million02/20/2024$2.01$1.97-1.99%$2.11$1.951.16 million shs$297.65 million02/19/2024$2.01$2.01$2.02$1.801.27 million shs$303.69 million02/16/2024$1.79$2.01+12.29%$2.02$1.801.27 million shs$303.69 million02/15/2024$1.73$1.79+3.47%$1.80$1.71530,883 shs$270.45 million02/14/2024$1.67$1.73+3.59%$1.76$1.69337,148 shs$261.39 million02/13/2024$1.83$1.67-8.74%$1.77$1.66684,136 shs$252.32 million02/12/2024$1.84$1.83-0.54%$1.89$1.80474,742 shs$276.50 million02/09/2024$1.76$1.84+4.55%$1.86$1.76492,220 shs$278.01 million02/08/2024$1.70$1.76+3.53%$1.77$1.70468,393 shs$265.92 million Related Companies: FibroBiologics Stock Price Chart Kamada Stock Price Chart Organogenesis Stock Price Chart Atea Pharmaceuticals Stock Price Chart Verrica Pharmaceuticals Stock Price Chart Silverback Therapeutics Stock Price Chart Neoleukin Therapeutics Stock Price Chart XOMA Stock Price Chart Black Diamond Therapeutics Stock Price Chart Enanta Pharmaceuticals Stock Price Chart Receive ERAS Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:ERAS) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersThis 1 Biotech Stock has been shocking the marketsHuge Alerts1970’s computer coder Issues Shocking AI WarningInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.